Employer-mandated high-deductible health plan enrollment was not associated with reduced use of oral targeted anticancer ...
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to ...
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...
Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...
Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...
FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.
Rotterdam-based diagnosis (2 of oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) persists, but ...
A finalized mandatory model will test whether tying Medicare Part B drug rebates to international prices can lower costs for ...
Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...
Without a functioning ACIP, Jeffery Goad, PharmD, MPH, explains who now guides COVID-19 vaccine use and how HMOs can stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results